Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-02-14 00:00:00 ET · period of report 2022-02-10 · accession 0001725160-22-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-14 | 2022-02-10 | ZNTL | Epperly Melissa B, | CFO | A - Grant | $0.00 | +16.4K | 266.4K | +7% | $0 |
| D | 2022-02-14 | 2022-02-10 | ZNTL | Epperly Melissa B, | CFO | A - Grant | $0.00 | +38.5K | 38.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-10 | A | A | 16,405 | $0.00 | 266,407 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-10 | A | A | 38,489 | $0.00 | 38,489 | D | $52.61 · — to 2032-02-09 | 38,489 Common Stock | (F2) The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. |